THE APEX TIMES
The bank’s view hinges on a valuation that, at roughly $87.1 billion in market value, is not fully supported by what it expects Moderna’s pipeline to deliver.
JPMorgan Chase is maintaining a skeptical stance on Moderna Inc., even after raising its price target for the biotechnology company, according to a report carried by Yahoo Finance.
The core of the bank’s argument is that Moderna’s market value, cited at $87.1 billion in the report, appears to be ahead of what its pipeline can ultimately justify, leaving what the bank describes as a gap between current valuation and expected future cash flows.
In the same coverage, JPMorgan is portrayed as taking a measured step forward by increasing its target price, but without changing its broader conclusion that the stock is still priced for more success than the pipeline, as JPMorgan frames it, supports.
Analyst price targets are not the same as forecasts of the next quarter’s earnings. They generally reflect assumptions about clinical trial outcomes, regulatory timelines, and the long-term commercial potential of a company’s products. When those assumptions are conservative, targets can rise modestly while the analyst still characterizes the stock as expensive relative to fundamentals.
For investors, JPMorgan’s stance highlights how quickly biotech valuation can become detached from near-term evidence, particularly when markets price in multiple catalysts. Moderna’s valuation is often tied to the durability of its vaccine platform and the prospects of follow-on programs. If results or timelines slip, the market can re-rate the stock downward even if long-term optionality remains.
The report does not lay out specific trial readouts, program-by-program revenue modeling, or the exact new target price in the information provided here. It also does not specify whether JPMorgan’s reassessment stemmed from revised probability assumptions, updated target discount rates, or other valuation mechanics beyond the general characterization of the pipeline-versus-valuation mismatch.
Even so, the framing matters because it suggests JPMorgan is not betting on a broad, immediate valuation correction. Instead, it implies the bank expects the path to value creation to take longer or be less certain than the market is currently pricing, which can influence how the stock responds to future clinical and regulatory updates.
The beverage alcohol maker said an executive will discuss company developments at the 2026 gathering of consumer and retail investors.
The alternative asset manager said its president and chief operating officer is scheduled to present at the Goldman Sachs event on Wednesday, according to a new announcement filed through market channels.
A recent report says the firm has shifted to an aggressive “maximum overweight” stance on S&P 500 stocks, indicating a change in how it expects equities to perform relative to cash or underweights.
Berkshire Hathaway disclosed a new position in Bending Spoons, the company behind brands including AOL and Evernote, marking a notable shift in its publicly reported equity buys, even as details on the rationale remain sparse.
The filing, reported by Yahoo Finance, would use a structure designed to combine the daily tradability investors associate with ETFs with the less liquid characteristics of certain private-market assets, potentially changing how large asset managers package alternatives.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...